Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors DA Wainwright, AL Chang, M Dey, IV Balyasnikova, CK Kim, A Tobias, ... Clinical cancer research 20 (20), 5290-5301, 2014 | 613 | 2014 |
CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells AL Chang, J Miska, DA Wainwright, M Dey, CV Rivetta, D Yu, D Kanojia, ... Cancer research 76 (19), 5671-5682, 2016 | 555 | 2016 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy B Auffinger, AL Tobias, Y Han, G Lee, D Guo, M Dey, MS Lesniak, ... Cell Death & Differentiation 21 (7), 1119-1131, 2014 | 380 | 2014 |
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet AC Filley, M Henriquez, M Dey Oncotarget 8 (53), 91779, 2017 | 356 | 2017 |
Inhibition of Sonic Hedgehog and Notch Pathways Enhances Sensitivity of CD133+ Glioma Stem Cells to Temozolomide Therapy IV Ulasov, S Nandi, M Dey, AM Sonabend, MS Lesniak Molecular medicine 17, 103-112, 2011 | 240 | 2011 |
External ventricular drainage for intraventricular hemorrhage M Dey, J Jaffe, A Stadnik, IA Awad Current neurology and neuroscience reports 12, 24-33, 2012 | 174 | 2012 |
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology WX Huff, JH Kwon, M Henriquez, K Fetcko, M Dey International journal of molecular sciences 20 (11), 2810, 2019 | 156 | 2019 |
Plasmacytoid dendritic cell in immunity and cancer D Mitchell, S Chintala, M Dey Journal of neuroimmunology 322, 63-73, 2018 | 150 | 2018 |
Immune system, friend or foe of oncolytic virotherapy? AC Filley, M Dey Frontiers in oncology 7, 106, 2017 | 142 | 2017 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study AB Heimberger, W Sun, SF Hussain, M Dey, L Crutcher, K Aldape, ... Neuro-oncology 10 (1), 98-103, 2008 | 140 | 2008 |
Targeting Tregs in malignant brain cancer: overcoming IDO DA Wainwright, M Dey, A Chang, MS Lesniak Frontiers in immunology 4, 116, 2013 | 136 | 2013 |
Primary central nervous system germ cell tumors: a review and update K Fetcko, M Dey Medical research archives 6 (3), 2018 | 102 | 2018 |
The role of IDO in brain tumor immunotherapy L Zhai, KL Lauing, AL Chang, M Dey, J Qian, Y Cheng, MS Lesniak, ... Journal of neuro-oncology 123, 395-403, 2015 | 102 | 2015 |
CART immunotherapy: development, success, and translation to malignant gliomas and other solid tumors AC Filley, M Henriquez, M Dey Frontiers in oncology 8, 453, 2018 | 95 | 2018 |
Bleeding and infection with external ventricular drainage: a systematic review in comparison with adjudicated adverse events in the ongoing Clot Lysis Evaluating Accelerated … M Dey, A Stadnik, F Riad, L Zhang, N McBee, C Kase, JR Carhuapoma, ... Neurosurgery 76 (3), 291-301, 2015 | 87 | 2015 |
Recent developments on immunotherapy for brain cancer DA Wainwright, P Nigam, B Thaci, M Dey, MS Lesniak Expert opinion on emerging drugs 17 (2), 181-202, 2012 | 76 | 2012 |
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma T Hasan, SP Caragher, JM Shireman, CH Park, F Atashi, S Baisiwala, ... Cell death & disease 10 (4), 292, 2019 | 73 | 2019 |
Spontaneous intracerebral and intraventricular hemorrhage: advances in minimally invasive surgery and thrombolytic evacuation, and lessons learned in recent trials M Dey, A Stadnik, IA Awad Neurosurgery 74, S142-S150, 2014 | 72 | 2014 |
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy L Zhai, M Dey, KL Lauing, G Gritsina, R Kaur, RV Lukas, MK Nicholas, ... Journal of Clinical Neuroscience 22 (12), 1964-1968, 2015 | 68 | 2015 |
Cancer stem cells: the final frontier for glioma virotherapy M Dey, IV Ulasov, MA Tyler, AM Sonabend, MS Lesniak Stem Cell Reviews and Reports 7, 119-129, 2011 | 63 | 2011 |